Cyr61 is a potential prognostic marker for prostate cancer

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 405-408

  Terada, Naoki ^a   Kulkarni, Prakash ^a   Getzenberg, Robert H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyr61; lethal prostate cancer; non lethal prostate cancer; overdiagnosis; overtreatment; prostate cancer

Indexed keywords

CYSTEINE RICH PROTEIN 61; GROWTH FACTOR; SCLEROPROTEIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; GENE EXPRESSION; HUMAN; PROGNOSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVIEW; SIGNAL TRANSDUCTION;

CYSTEINE-RICH PROTEIN 61; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860873202     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.149     Document Type: Review

References (43)

1. O'Brien TP, Yang GP, Sanders L, Lau LF. Expression of Cyr61, a growth factorinducible immediate-early gene. Mol Cell Biol 1990; 10: 3569-3577. (Pubitemid 20198182)
2. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: A cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991; 114: 1285-1294. (Pubitemid 21909886)
3. Joliot V, Martinerie C, Dambrine G, Plassiart G, BrisacMet al. Proviral rearrangements and overexpression of a new cellular gene (Nov) in myeloblastosis-Associated virus type 1-induced nephroblastomas. Mol Cell Biol 1992; 12: 10-21.
4. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-Transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA 1998; 95: 14717-22. (Pubitemid 29003696)
5. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993; 327: 125-130. (Pubitemid 23211174)
6. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009; 41: 771-783.
7. Bleau AM, Planque N, Perbal B. CCN proteins and cancer: Two to tango. Front Biosci 2005; 10: 998-1009.
8. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP et al. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005; 11: 5809-5820.
9. Feng P, Wang B, Ren EC. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int J Biochem Cell Biol 2008; 40: 98-109. (Pubitemid 350064578)
10. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr et al. Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 2005; 200: 371-377. (Pubitemid 40298971)
11. Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM et al. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 2004; 279: 53087-96. (Pubitemid 40051809)
12. Tsai MS, Hornby AE, Lakins J, Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000; 60: 5603-5607.
13. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001; 276: 14187-94.
14. Menendez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor CYR61 in breast cancer: Molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003; 10: 141-152. (Pubitemid 36758643)
15. Xie D, Yin D, Tong X, O'Kelly J, Mori A et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 2004; 64: 1987-1996. (Pubitemid 38339444)
16. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10: 2072-2081. (Pubitemid 38375569)
17. Tong X, Xie D, O'Kelly J, Miller CW, Muller-Tidow C et al. Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 2001; 276: 47709-14.
18. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I et al. Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays. Proc Natl Acad Sci USA 2002; 99: 7598-7603. (Pubitemid 34568737)
19. D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA et al. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. J Urol 2010; 183: 1604-1610.
20. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE et al. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998; 36: 85-91. (Pubitemid 28311312)
21. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6. (Pubitemid 38391943)
22. Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ et al. Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer 2008; 99: 1656-1667.
23. Franzen CA, Chen CC, Todorovic V, Juric V, Monzon RI et al. Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol Cancer Res 2009; 7: 1045-1055.
24. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: Review of current literature. Histopathology 2005; 47: 1-16. (Pubitemid 40978808)
25. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR et al. Alphamethylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-1670. (Pubitemid 34289218)
26. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL et al. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220-2226. (Pubitemid 34411693)
27. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-Analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002; 62: 4427-4433. (Pubitemid 34827303)
28. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: Alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol 2004; 122: 275-289. (Pubitemid 38971361)
29. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007; 60: 35-42. (Pubitemid 46142669)
30. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M et al. Alpha-methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002; 161: 841-848. (Pubitemid 34988371)
31. Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): A novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004; 164: 831-840. (Pubitemid 38235465)
32. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005; 14: 1424-1432. (Pubitemid 40807341)
33. D'Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA et al. Decreased expression of cyr61 is associated with prostate cancer recurrence after surgical treatment. Clin Cancer Res 2010; 16: 5908-5913.
34. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61: 8917-8923. (Pubitemid 34013909)
35. Karan D, Thrasher JB, Lubaroff D. Prostate cancer: genes, environment, immunity and the use of immunotherapy. Prostate Cancer Prostatic Dis 2008; 11: 230-236.
36. Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007; 100: 1337-1345. (Pubitemid 46515568)
37. Terada N, Shiraishi T, Zeng Y, Mooney SM, Yeater DB et al. Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. Prostate; e-pub ahead of print 24 October 2011; doi: 10.1002/pros.21501.
38. Sakamoto S, Yokoyama M, Prakash K, Tsuruha J, Masamoto S et al. Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. J Biomol Screen 2003; 8: 701-711.
39. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-848. (Pubitemid 34017254)
40. Kandirali E, Boran C, Serin E, Semercioz A, Metin A. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 2007; 70: 743-747. (Pubitemid 350030236)
41. Sakamoto S, Yokoyama M, Aoki M, Suzuki K, Kakehi Y et al. Induction and function of CYR61 (CCN1) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. Prostate 2004; 61: 305-317. (Pubitemid 39564275)
42. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-3593. (Pubitemid 23152669)
43. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-534.(Pubitemid 34074521)